Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC16A3 | O15427 | 3/20 | 0.38 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | FABP3 | P05413 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10698208 | 0.87 | PDE4B (0.42) | PDE4BRIPK1MEN1KMT2ASLC16A3 | |
| SCHEMBL27629217 | 0.82 | FABP3 (0.51) | SLC16A3SLC16A1ALDH1A1FABP3FABP4 | |
| SCHEMBL3250915 | 0.82 | MARS1 (0.39) | RIPK1ALDH1A1NOTUMMAPK14 | |
| SCHEMBL27714814 | 0.78 | MARS1 (0.48) | MEN1KMT2ASLC16A3SLC16A1FABP3 | |
| SCHEMBL10388627 | 0.76 | RXRA (0.52) | PDE4BRIPK1MEN1KMT2ANPC1 | |
| SCHEMBL27716960 | 0.76 | RXRA (0.45) | PDE4BRIPK1MEN1KMT2ASLC16A3 | |
| SCHEMBL4917405 | 0.75 | KDM4E (0.50) | PDE4BRIPK1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1460410 | 0.75 | PDE4B (0.44) | PDE4BRIPK1MEN1KMT2ANPC1 | |
| SCHEMBL2320840 | 0.75 | MARS1 (0.51) | MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL10698162 | 0.74 | MEN1 (0.44) | PDE4BMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180235976-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2018-08-23 | — | — | US | disclosed |
| EP-2860179-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SUISSE SA (CH) | 2018-03-14 | — | — | EP | disclosed |
| EP-2483271-B1 | PYRAZOLINE DIONE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SUISSE SA (CH) | 2017-08-16 | — | — | EP | disclosed |
| CN-102686590-B | As the pyrazoline derovatives of nadph oxidase inhibition | GENKYOTEX S.A. (CH) | 2015-09-16 | — | — | CN | disclosed |
| EP-2860179-A1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GenKyoTex SA (CH) | 2015-04-15 | — | — | EP | disclosed |
| EP-2344492-B1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2014-10-29 | — | — | EP | disclosed |
| CN-102686590-A | Pyrazoline dione derivatives as NADPH oxidase inhibitors | GENKYOTEX SA | 2012-09-19 | — | — | CN | disclosed |
| EP-2483271-A1 | PYRAZOLINE DIONE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GenKyoTex SA (CH) | 2012-08-08 | — | — | EP | disclosed |
| WO-2010035221-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010035219-A2 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-04-01 | — | — | WO | disclosed |
| EP-2166010-A1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYO TEX SA (CH) | 2010-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180235976-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | PDE4B 370/4885RIPK1 2785/4885MEN1 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.